IRMEIR-Med Inc.

About IR-Med Inc. (IRME)

IR-Med Inc. (IRME) is a Medical Devices company headquartered in Rosh Pina, Israel whose shares trade over-the-counter on the OTCQB tier.

IIR-Med, Inc. and its consolidated Subsidiary, IR. Med Ltd. is an innovative med-tech company focused on leveraging Infra-Red light for medical application. IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI based process to provide healthcare professionals with decision support in the assessment of various medical conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize the assessment of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contribute to assessment of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue assessment.

Products and services

Our initial product under development, which we call PressureSafe, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone and which calibrated personally to each patient’s skin, primarily caused by prolonged pressure associated with bed confinement. Our skin-device-interphase development of personalized medical devices allows high accuracy readings from the human body in a non-invasive method, that may provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes. We plan to launch as a decision support system (DSS) tool for care givers in Hospitals, Nursing homes and Home-Care companies, We are also developing an innovative otoscope, which we call Nobiotics, to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children, is of a bacterial origin and thus requiring antibiotic treatment, or of a viral origin and does not require antibiotic treatment. Our technology platform utilizes Artificial Intelligence (AI). AI is a broad term generally used to describe conditions where a machine mimics “cognitive” functions associated with human intelligence, such as “learning” and “problem solving. Basic

IRME key facts

Ticker symbol

IRME

Market tier

OTCQB

Sector

Healthcare

Industry

Medical Devices

Headquarters

Rosh Pina, Israel

Country of incorporation

US

Year of incorporation

2007

Employees

6

Estimated market cap

$12.24M (as of Apr 15, 2025)

Shares outstanding

72,008,144

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

IR-Med Inc. leadership

• Ran Ziskind — CEO
• Yaniv Cohen — CSO
• Sharon David Levkoviz — CFO
• Aharon Klein — CTO
• Aharon Binur — Chief Development Officer

Explore more: Medical Devices stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with I